Microbicides to prevent HIV transmission: Overcoming obstacles to chemical barrier protection

被引:35
作者
Dhawan, D
Mayer, KH
机构
[1] Brown Univ, Miriam Hosp, Div Infect Dis, Providence, RI 02906 USA
[2] Brown Univ, Miriam Hosp, Brown Med Sch, Providence, RI 02906 USA
[3] Fenway Community Hlth, Boston, MA USA
关键词
D O I
10.1086/499163
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Microbicides are topical compounds that could prevent sexually transmitted infections. Several compounds have demonstrated activity both in vitro and in animal models, but none has been approved for use in humans. Methods. A review of 1100 recent publications from MEDLINE (through October 2005) and abstracts presented at recent conferences was undertaken to describe the current status of microbicide research and to delineate why microbicides are not yet available. Results. More than 15 candidate microbicides are currently being studied in clinical trials. Their mechanisms of action include disruption of the viral membrane by surfactants, maintenance of an acidic vaginal pH, binding to the viral envelope to block receptor binding, and blocking of receptors; they may also be combined with antiretroviral drugs. The development of safe and effective microbicides has been delayed by limitations in understanding the biological processes of human immunodeficiency virus (HIV) transmission, difficulties in extrapolation from animal models, lack of established correlates of protection, and the need to enroll and follow large cohorts of high-risk participants for several years in order to demonstrate efficacy. Conclusions. Safe and effective topical microbicides are biologically plausible. Several trials that are under way may demonstrate the ability of microbicides to protect against transmission of HIV, but multiple challenges remain.
引用
收藏
页码:36 / 44
页数:9
相关论文
共 123 条
[1]   A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection [J].
Abner, SR ;
Guenthner, PC ;
Guarner, J ;
Hancock, KA ;
Cummins, JE ;
Fink, A ;
Gilmore, GT ;
Staley, C ;
Ward, A ;
Ali, O ;
Binderow, S ;
Cohen, S ;
Grohskopf, LA ;
Paxton, L ;
Hart, CE ;
Dezzutti, CS .
JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (09) :1545-1556
[2]   Trial of antiretroviral for HIV prevention on hold [J].
Ahmad, K .
LANCET INFECTIOUS DISEASES, 2004, 4 (10) :597-597
[3]   CC CKRS: A RANTES, MIP-1 alpha, MIP-1 beta receptor as a fusion cofactor for macrophage-tropic HIV-1 [J].
Alkhatib, G ;
Combadiere, C ;
Broder, CC ;
Feng, Y ;
Kennedy, PE ;
Murphy, PM ;
Berger, EA .
SCIENCE, 1996, 272 (5270) :1955-1958
[4]  
[Anonymous], AIDS EP UPD
[5]  
[Anonymous], 2001, WHO CONRAD TECHN CON
[6]   In vivo distribution of a vaginal gel: MRI evaluation of the effects of gel volume, time and simulated intercourse [J].
Barnhart, KT ;
Pretorius, ES ;
Timbers, K ;
Shera, D ;
Shabbout, M ;
Malamud, D .
CONTRACEPTION, 2004, 70 (06) :498-505
[7]   Microbicides - evaluating multiple formulations of C31G [J].
Bax, R ;
Douville, K ;
McCormick, D ;
Rosenberg, M ;
Higgins, J ;
Bowden, M .
CONTRACEPTION, 2002, 66 (05) :365-368
[8]   Acceptability of a microbicide among women and their partners in a 4-country phase I trial [J].
Bentley, ME ;
Fullem, AM ;
Tolley, EE ;
Kelly, CW ;
Jogelkar, N ;
Srirak, N ;
Mwafulirwa, L ;
Khumalo-Sakutukwa, G ;
Celentano, DD .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2004, 94 (07) :1159-1164
[9]  
BOLLEN L, 2002, PHOTO ATLAS MICROBIC
[10]   Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: Retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase [J].
Borkow, G ;
Barnard, J ;
Nguyen, TM ;
Belmonte, A ;
Wainberg, MA ;
Parniak, MA .
JOURNAL OF VIROLOGY, 1997, 71 (04) :3023-3030